Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

This study found that a combination of topical minoxidil and finasteride helped maintain hair density in patients with androgenetic alopecia after initial oral finasteride treatment.

This review discusses the historical development and current challenges in in vitro hair follicle culture, highlighting a need for advanced models using cell lines and tissue engineering, and reports no new results.

This study found that certain trichoscopic features like white peripilar sign, yellow dots, and scalp pigmentation are positively correlated with the severity of androgenetic alopecia in Chinese patients.

This study found that miniaturization of hair is present in some women with androgenetic alopecia, but diagnosis may also be based on differences in hair shaft diameter between scalp regions.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

In this study, researchers found that the existing Norwood and Hamilton classifications for androgenetic alopecia in Indian males had significant limitations, with 18% of cases not fitting into existing pattern categories.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.

In this study, researchers found that a polyphenolic extract from Annurca apples, high in procyanidin B2, increased hair growth, density, and keratin content in healthy subjects after 2 months of use, and stimulated keratin biosynthesis in vitro.

This review discusses the research supporting the approval and use of minoxidil for androgenic alopecia and reports no new clinical results, emphasizing recent findings and developments.

In this study, quercitrin was reported to promote hair growth and cell viability in cultured human dermal papilla cells by enhancing cellular energy metabolism and growth factor production via MAPK/CREB signaling.

This article discusses the hormonal mechanisms contributing to acne and suggests dietary changes to reduce these hormones but reports no new clinical results.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.

This study found that among Caucasian individuals with androgenetic alopecia, being overweight and smoking were associated with greater severity of the condition.

This study found no significant difference in serum and hair levels of iron, zinc, and copper between female alopecia areata patients and healthy controls.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

This study highlights the significant psychological impact of alopecia areata, emphasizing the reciprocal relationship between the disorder and psychiatric issues, and underscores the importance of identifying patients needing additional psychological support, especially women, young individuals, and those with severe alopecia or previous psychiatric history.

This study found that 5% minoxidil topical foam was effective in stabilizing hair density and scalp coverage in men with moderate androgenetic alopecia over 104 weeks, with good safety and tolerability.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

This article discusses a potential link between adipocyte-myofibroblast transition and androgenetic alopecia, suggesting AMT may play a role in fibrosis associated with the condition but presents no new results.

This study suggests the average age of onset for androgenic alopecia may be decreasing, but a longer-term study is needed to confirm this observation.

This review discusses recent genetic findings on hormonal signaling pathways in androgenetic alopecia, reporting no new study results but highlighting the need for further investigation.

This study found that 1,540 nm fractional erbium-glass laser treatment combined with topical minoxidil significantly increased hair regrowth in alopecia areata patches compared to minoxidil alone, with response rates of 60% versus 16%, though the long-term effects remain unknown.

This study found no significant association between androgenetic alopecia and metabolic syndrome, though systolic blood pressure was higher in the alopecia group compared to controls.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

This study found that phyto-vesicles of ß-sitosterol showed better absorption and improved activity for treating androgenetic alopecia in rats compared to the compound and its complex.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.